Cargando…
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis®) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Pha...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360276/ https://www.ncbi.nlm.nih.gov/pubmed/18000504 http://dx.doi.org/10.1038/sj.bjc.6604088 |